Proceedings of the National Academy of Sciences · 2020 · 115 citations · 23 references
Life SciencesMolecular BiologyOncologyCarcinogenesisGene ExpressionMolecular OncologyCancer Cell SignalingPost-translational RegulationTargeted Cancer TherapyTranslational RegulationTumor Suppressor GenesAnticancer ActivityAnticancer ChemotherapyEstrogen Receptor SignalingProtein ModificationsTranslational ActivationTumor Suppressor Pathways
Precisely controlling the activation of transcription factors is crucial for physiology. After a transcription factor is activated and carries out its transcriptional activity, it also needs to be properly deactivated. Here, we report a deactivation mechanism of HIF-1 and several other oncogenic transcription factors. HIF-1 promotes the transcription of an ADP ribosyltransferase, TiPARP, which serves to deactivate HIF-1. Mechanistically, TiPARP forms distinct nuclear condensates or nuclear bodies in an ADP ribosylation-dependent manner. The TiPARP nuclear bodies recruit both HIF-1α and an E3 ubiquitin ligase HUWE1, which promotes the ubiquitination and degradation of HIF-1α. Similarly, TiPARP promotes the degradation of c-Myc and estrogen receptor. By suppressing HIF-1α and other oncogenic transcription factors, TiPARP exerts strong antitumor effects both in cell culture and in mouse xenograft models. Our work reveals TiPARP as a negative-feedback regulator for multiple oncogenic transcription factors, provides insights into the functions of protein ADP-ribosylation, and suggests activating TiPARP as an anticancer strategy.
23
Gregg L. Semenza, G.L. Wang · Molecular and Cellular Biology · 1992 · 2.4K citations · Full text
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
Hua Zhong, Angelo M. De Marzo, Erik Laughner et al. · PubMed · 1999 · 2.2K citations
Medicine, Cancer Biology, Oncology +14
Katherine Louise Talks, Helen Turley, Kevin C. Gatter et al. · American Journal Of Pathology · 2000 · 1.3K citations
Medicine, Cancer Biology, Oncology +16